Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)

Published:2020-01 Issue:1 Volume:156 Page:45-53
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Roncolato F.T.,O'Connell R.L.,Joly F.,Lanceley A.,Hilpert F.,Buizen L.,Okamoto A.,Aotani E.,Salutari V.,Donnellan P.,Oza A.,Avall-Lundqvist E.,Berek J.,Fehm T.,Ledermann J.,Roemer-Becuwe C.,Stockler M.R.,King M.T.,Friedlander M.L.

Funder

Astra Zeneca

Roche

Tesaro

Janssen

BMS

Astellas

Pfizer

Sanofi

Ipsen

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference20 articles.

1. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy;Hanker;Ann. Oncol.,2012

2. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients;Wagner;Br. J. Canc.,2012

3. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial;Audeh;The Lancet,2010

4. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial;Ledermann;Lancet Oncol.,2014

5. Reducing uncertainty: predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—the GCIG symptom benefit study;Roncolato;The Oncologist,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life clinical benefit of oral metronomic cyclophosphamide administration in elderly and heavily pretreated epithelial ovarian cancer patients;Archives of Gynecology and Obstetrics;2024-08-02

2. Systematic Review of the Literature on Multiple Co-occurring Symptoms in Patients Receiving Treatment for Gynecologic Cancers;Seminars in Oncology Nursing;2024-02

3. Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice;Patient Related Outcome Measures;2023-05

4. Quality of life of ovarian cancer patients treated with combined platinum taxane chemotherapy: a systematic review of the literature;Supportive Care in Cancer;2022-04-23

5. Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study;International Journal of Gynecologic Cancer;2022-01-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3